Capecitabine and docetaxel in treating the metastatic breast cancer

At present, docetaxel and capecitabine is high efficacy in treating advanced breast cancer drug, they combined medication effect is obvious, is recognized as the preferred treatment options. Recent literature reported, combined with the two drugs has significant advantages than single one of them, such as in the tumor remission rate, time to progression and overall survival.

Breast cancer is the most common malignant tumor in female. Incidence in china shows ascendant trend. Data shows that, 5%-15% of breast cancer patients with clinically diagnosed had distant metastases, in some underdeveloped areas even up to 20%-25%, for such patients, chemotherapy is the main treatment. Anthracycline chemotherapy drugs in breast cancer is chemotherapy based drug, and along with the clinical research and application, recent reports by docetaxel manufacturershow that the combined application of docetaxel and capecitabine is most effective drugs following by anthracycline treating breast cancer after failure. Both combined with medicine can improve the curative effect, but no obvious adverse reaction increase.

Docetaxel belongs to paclitaxel drug, it is a semi-synthetic. Its mechanism is related to the free tubulin binding, promote tubulin polymerization, and inhibition of its depolymerization. The results make it stable, thereby blocking tumor cell mitosis, inhibition of tumor cell replication, killing tumor cells, to achieve the antitumor effect, so the current of docetaxel in the treatment of metastatic breast cancer is one of the most effective drugs.

Capecitabine is pharmaceutical raw materials, approved by FDA of a class in tumor cell activation, and oral fluorinated pyrimidine, after oral administration can be integrally through gastrointestinal tract mucosa absorption, after the 3 steps unique activation mechanisms, reach the tumor tissue after it is converted into 5-Fu cells and play toxic effect. Its mechanism of action is in the S phase of the cell cycle of tumor cells, with highly targeted, compared with 5-Fu its anticancer effect is enhanced, reducing side effect.

Capecitabine plus docetaxel therapy for breast cancer is relatively good, especially after menopause and the ER receptor and PR receptor positive patients is better. For anorexia, nausea, vomiting, may be rehydration, antiemetic therapy; elevated transaminases to liver transaminase, such treatment; for the neutropenic patients to colony stimulating factor after treatment, can be on time receiving chemotherapy and can complete the entire course of chemotherapy; individual patients developed hand-foot syndrome, stomatitis, phlebitis, allergy, are improving after given the corresponding treatment.

To sum up, docetaxel combined with capecitabine in treating metastatic breast cancer can achieve good curative effect in the near future, and the adverse reactions can be tolerated, can be controlled through corresponding methods, no treatment termination because of obvious adverse reactions. The combined application of the two drugs can improve the quality of patients’ life, clinical tumor control rate is good, consistent with the aim of treating advanced cancer.

Source:http://www.cospcn.com